The circadian rhythm of biochemical markers of bone resorption is normally synchronized in breast cancer patients with bone lytic metastases independently of tumor load

Generali, Daniele; Berruti, Alfredo; Tampellini, Marco; Dovio, Andrea; Tedoldi, Sara; Bonardi, S; Tucci, Marco; Allevi, Giovanni; Aguggini, Sergio; Milani, Manuela; Bottini, Alberto; Dogliotti, Luigi; Angeli, Alberto

doi:10.1016/j.bone.2006.06.023

Cited by 21 publications

(13 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A predetermined period (τ=24 h for circadian, 12 h for circasemidian) was chosen to fit a cosine curve to the data series. Correlation coefficient constant and mean square error determine the goodnessof-fit of the cosine curve [18]. The analysis yields three main parameters: midline estimating statistics of the rhythm (MESOR) of the fitted cosine curve, acrophase (occurrence of the estimated peak time, which may not be coincident with the time at which maximum concentration was observed), and amplitude (half the difference between the highest and the lowest points of the fitted cosine curve).…”

Section: Subjects Materials and Methodsmentioning

confidence: 99%

Variations along the 24-hour cycle of circulating osteoprotegerin and soluble RANKL: a rhythmometric analysis

et al. 2007

View full text Add to dashboard Cite

Summary The variability of serum osteoprotegerin (OPG) and soluble RANKL (sRANKL) along the 24-h cycle was assessed in 20 healthy women. No rhythmic variations of serum OPG, sRANKL or sRANKL/OPG ratio were detected as a group phenomenon. Timing of sampling is unlikely to influence the results of measurements of circulating OPG and sRANKL. Introduction Physiological bone turnover shows diurnal variations. The aim of the study was to assess variability of OPG and sRANKL serum levels along the 24-h cycle. Methods Blood was collected from 20 healthy women (median age 31 years, range 25-65 years) at 4-h intervals between 08:00 and 24:00 and at 2-h intervals between 24:00 and 08:00. Serum albumin, cortisol, osteocalcin (OC), Cterminal telopeptide of type I collagen (CTX), OPG and total sRANKL were measured. Temporal variations were assessed by the COSINOR model. Results Circadian rhythms of cortisol and albumin documented a normal synchronization within the circadian structure. Serum OC and CTX showed rhythmic variations, peaking at night-time. Rhythmic variations of serum OPG, sRANKL and sRANKL/OPG ratio were not detected as a group phenomenon. On an individual basis, rhythmic changes were detected in ten patients for OPG and eight patients for sRANKL, with very small amplitudes and heterogeneous acrophases. Conclusions The absence of consistent rhythmic variations of circulating OPG and sRANKL levels may reflect the absence of rhythmic variations of their expression in the bone microenvironment. Were this the case, the nocturnal rise of bone resorption should be accounted for by different, not RANKL/OPG-mediated factors. Since circulating OPG and sRANKL may derive from sources other than bone, rhythmicity could be masked by non-rhythmic or nonsynchronized rhythmic expression in these sources. Timing of sampling is unlikely to influence the results of measurements of circulating OPG and sRANKL.

show abstract

Section: Subjects Materials and Methodsmentioning

confidence: 99%

Variations along the 24-hour cycle of circulating osteoprotegerin and soluble RANKL: a rhythmometric analysis

et al. 2007

View full text Add to dashboard Cite

show abstract

“…Despite image harmonization, we found that for all 3 SUV metrics, the variance in lesion-level test-retest measurements was significantly smaller at UWCCC than at the other sites. The repeatability differences between sites might have been due to physiologic factors such as circadian rhythm or different degrees of conformation to the imaging protocol (29,30). For example, the mean (6SD) postinjection time (61 6 1 min at UWCCC vs. 69 6 9 min at MSKCC) and injected dose (178 6 9 MBq at UWCCC vs. 136 6 32 MBq at NCI) varied by site (Supplemental Table 1; supplemental materials are available at http://jnm.…”

Section: Discussionmentioning

confidence: 99%

Repeatability of Quantitative ¹⁸F-NaF PET: A Multicenter Study

et al. 2016

View full text Add to dashboard Cite

18 F-NaF, a PET radiotracer of bone turnover, has shown potential as an imaging biomarker for assessing the response of bone metastases to therapy. This study aimed to evaluate the repeatability of 18 F-NaF PET-derived SUV imaging metrics in individual bone lesions from patients in a multicenter study. Methods: Thirty-five castration-resistant prostate cancer patients with multiple metastases underwent 2 whole-body (test-retest) 18 F-NaF PET/CT scans 3 ± 2 d apart from 1 of 3 imaging sites. A total of 411 bone lesions larger than 1.5 cm 3 were automatically segmented using an SUV threshold of 15 g/mL. Two levels of analysis were performed: lesion-level, in which measures were extracted from individual-lesion regions of interest (ROI), and patient-level, in which all lesions within a patient were grouped into a patient ROI for analysis. Uptake was quantified with SUV max , SUV mean , and SUV total . Test-retest repeatability was assessed using BlandAltman analysis, intraclass correlation coefficient (ICC), coefficient of variation, critical percentage difference, and repeatability coefficient. The 95% limit of agreement (LOA) of the ratio between test and retest measurements was calculated. Results: At the lesion level, the coefficient of variation for SUV max , SUV mean , and SUV total was 14.1%, 6.6%, and 25.5%, respectively. At the patient level, it was slightly smaller: 12.0%, 5.3%, and 18.5%, respectively. ICC was excellent (.0.95) for all SUV metrics. Lesion-level 95% LOA for SUV max, SUV mean , and SUV total was (0.76, 1.32), (0.88, 1.14), and (0.63, 1.71), respectively. Patient-level 95% LOA was slightly narrower, at (0.79, 1.26), (0.89, 1.10), and (0.70, 1.44), respectively. We observed significant differences in the variance and sample mean of lesion-level and patient-level measurements between imaging sites. Conclusion: The repeatability of SUV max , SUV mean , and SUV total for 18 F-NaF PET/CT was similar between lesion-and patient-level ROIs. We found significant differences in lesion-level and patient-level distributions between sites. These results can be used to establish 18 F-NaF PET-based criteria for assessing treatment response at the lesion and patient levels. 18 F-NaF PET demonstrates repeatability levels useful for clinically quantifying the response of bone lesions to therapy.

show abstract

“…There was also interindividual variability in the return to baseline (between 06:00 and 10:00) [81,91]. Most studies reported a circadian amplitude amongst healthy individuals of between 0.3 and 0.8 pmol/L [64,66,68,69,72,73,75,77,79,81,82,90] although higher amplitudes of 1.2 [73] and 1.9 [68] pmol/L, respectively, were also reported. Circadian variation was absent in patients with thalassemia [70] and primary hyperparathyroidism [80,81].…”

Section: Circadian Variationmentioning

confidence: 99%

“…Logue et al [81] recommend that blood samples should be collected between 10:00 and 16:00 and results interpreted against a reference range based on this [65] 12.00-20.00 -20.00 08.00 Calvo et al [67] 02.00-04.00 18.00-20.00 18.00 and 02.00 10.00 and 20.00 Chapotot et al [68] 23.00-07.00 15.00-23.00 --El-Hajj et al [69] 01.00-03.00 17.30 03.14 10.00-11.00 Fraser et al [71] 22.00-07.00 14.00-22.00 06.12 09.30-10.30 Generali et al [72] --17.15 -Greenspan et al [74] 03.20 15.20 -12.00 Greenspan et al [75] 23.35 ± 05.25 , 20.30 ± 02.10 ---Herfarth et al [76] No night samples P.M. 14.00 09.30 Joseph et al [77] 22.00-24.00 , 24.00-02.00 14.00-17.00 09.46-13.15 , 10.45-13.25 -Jubiz et al [78] 02.00-04.00 --08.00 Kitamura et al [79] A.M. -23.00 ± 4 -Logue et al [82] 02.00-06.00 -04.05 10.00 Logue et al [81] A.M. -04.05 09.30 Markowitz et al [83] 04.00 20.00 --Nielsen et al [84] P.M. sampling time. Since the data were derived using first or second generation assays, it is possible that the reported diurnal variation of PTH could reflect differential clearance of PTH fragments over a 24 h period, e.g., with reduced renal clearance of (7-84) PTH at night reflecting decreased glomerular filtration rate at night [92].…”

Section: Circadian Variationmentioning

confidence: 99%

Sampling and storage conditions influencing the measurement of parathyroid hormone in blood samples: a systematic review

Hanon

Sturgeon

Lamb

2013

Clinical Chemistry and Laboratory Medicine (CCLM)

View full text Add to dashboard Cite

Parathyroid hormone (PTH) is relatively unstable: optimisation of pre-analytical conditions, including specimen type, sampling time and storage conditions, is essential. We have undertaken a systematic review of these pre-analytical conditions. An electronic search of the PubMed, Embase, Cochrane, Centre for Research and Dissemination and Bandolier databases was undertaken. Of 5511 papers identified, 96 underwent full text review, of which 83 were finally included. At room temperature PTH was stable in ethylenediaminetetraacetic acid (EDTA) preserved whole blood for at least 24 h and in EDTA plasma for at least 48 h after venepuncture. Losses were observed in clotted blood samples after 3 h and in serum after 2 h. At 4°C PTH was more stable in EDTA plasma (at least 72 h) than serum (at least 24 h). Central venous PTH concentrations were higher than peripheral venous concentrations. In the northern hemisphere, PTH concentrations were higher in winter than summer. PTH has a circadian rhythm characterised by a nocturnal acrophase and mid-morning nadir. Data related to frozen storage of PTH (−20°C and −80°C) were limited and contradictory. We recommend that blood samples for PTH measurement should be taken into tubes containing EDTA, ideally between 10:00 and 16:00, and plasma separated within 24 h of venepuncture. Plasma samples should be stored at 4°C and analysed within 72 h of venepuncture. Particular regard must be paid to the venepuncture site when interpreting PTH concentration. Further research is required to clarify the suitability of freezing samples prior to PTH measurement.

show abstract

The circadian rhythm of biochemical markers of bone resorption is normally synchronized in breast cancer patients with bone lytic metastases independently of tumor load

Cited by 21 publications

References 24 publications

Variations along the 24-hour cycle of circulating osteoprotegerin and soluble RANKL: a rhythmometric analysis

Variations along the 24-hour cycle of circulating osteoprotegerin and soluble RANKL: a rhythmometric analysis

Repeatability of Quantitative ¹⁸F-NaF PET: A Multicenter Study

Sampling and storage conditions influencing the measurement of parathyroid hormone in blood samples: a systematic review

Contact Info

Product

Resources

About

The circadian rhythm of biochemical markers of bone resorption is normally synchronized in breast cancer patients with bone lytic metastases independently of tumor load

Cited by 21 publications

References 24 publications

Variations along the 24-hour cycle of circulating osteoprotegerin and soluble RANKL: a rhythmometric analysis

Variations along the 24-hour cycle of circulating osteoprotegerin and soluble RANKL: a rhythmometric analysis

Repeatability of Quantitative 18F-NaF PET: A Multicenter Study

Sampling and storage conditions influencing the measurement of parathyroid hormone in blood samples: a systematic review

Contact Info

Product

Resources

About

Repeatability of Quantitative ¹⁸F-NaF PET: A Multicenter Study